| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/21/2006 | US7014846 polyallylamine hydrochloride crosslinked with epichlorohydrin; phosphate removal from gastrointestinal tract; hyperphosphatemia; side effect reduction |
| 03/21/2006 | US7014845 copolymer of a polysaccharide and a vinyl or acrylic polymer crosslinked with a diamine, amino acid or polypeptide; sustained release; as the polysaccharide is degraded by intestinal bacteria, an active steroidal or nonsteroidal drug is released for effective absorption |
| 03/21/2006 | US7014841 Delivery of antiemetics through an inhalation route |
| 03/21/2006 | US7014840 heating a thin coating to form a vapor then allowing to cool to form a condensation aerosol; kits |
| 03/21/2006 | US7014810 Method of producing solid shape forms containing an active ingredient |
| 03/21/2006 | US7014636 Tapering fluid flow channels; capsule; controlling fluid flow; determination pressure; drug delivery |
| 03/21/2006 | CA2520337A1 Medicinal cooling emulsions |
| 03/21/2006 | CA2369715C Fast-dispersing dosage forms containing fish gelatin |
| 03/21/2006 | CA2258159C Intraorally rapidly disintegrable tablet |
| 03/21/2006 | CA2189863C Mucoadhesive emulsions containing cyclodextrin |
| 03/21/2006 | CA2135535C Medicinal formulations containing thioctic acid or dihydrolipoic acid in the form of inclusion compounds with cyclodextrins or cyclodextrin derivatives and in the form of granulates, chewable or effervescent tablets |
| 03/16/2006 | WO2006029074A2 Methods for transmembrane treatment and prevention of otitis media |
| 03/16/2006 | WO2006029047A2 Sunless tanning system |
| 03/16/2006 | WO2006028996A2 Emulsan-alginate microspheres and methods of use thereof |
| 03/16/2006 | WO2006028939A1 Controlled and directed local delivery of anti-inflammatory compositions |
| 03/16/2006 | WO2006028831A2 Compositions comprising 5-amino-2-hydroxybenzoic acid and a reducing sugar |
| 03/16/2006 | WO2006028830A2 Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax |
| 03/16/2006 | WO2006028786A2 Preserved fusogenic vesicles |
| 03/16/2006 | WO2006028361A1 Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof |
| 03/16/2006 | WO2006028270A1 Rebamipide preparation for rectal administration to be prepared before using |
| 03/16/2006 | WO2006028214A1 Vaccine for oral administration |
| 03/16/2006 | WO2006028110A1 Process for producing water-soluble hyaluronic acid modification |
| 03/16/2006 | WO2006028074A1 Process for producing finely particulate substance and finely particulate substance |
| 03/16/2006 | WO2006027787A1 Liposomal compositions of glucocorticoid and glucocorticoid derivatives |
| 03/16/2006 | WO2006027786A2 Use of liposomal glucocorticoids for treating inflammatory states |
| 03/16/2006 | WO2006027785A1 Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions |
| 03/16/2006 | WO2006027688A1 Marking articles |
| 03/16/2006 | WO2006027278A1 Testosterone gels comprising propylene glycol as penetration enhancer |
| 03/16/2006 | WO2006027266A1 Tablets with site time-controlled gastrointestinal release of active ingredient |
| 03/16/2006 | WO2006027116A2 P277 peptide formulations or variants thereof having optimised stability |
| 03/16/2006 | WO2006026935A2 Pharmaceutical composition for rectal or vaginal application comprising a platinum complex |
| 03/16/2006 | WO2006026928A1 The vulneraria and the method for producing and using it |
| 03/16/2006 | WO2006026840A2 Controlled release delivery system for bio-active agents |
| 03/16/2006 | WO2006026829A1 Stable paste composition of enteric coated acid labile active agent and use thereof |
| 03/16/2006 | WO2006017341A3 Coated vaginal devices for vaginal delivery of therapeutically effective and/ or health-promoting agents |
| 03/16/2006 | WO2006002366A3 Biodegradable ocular devices, methods and systems |
| 03/16/2006 | WO2005120461A3 Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| 03/16/2006 | WO2005115441A3 Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| 03/16/2006 | WO2005112569A3 Methods for compounding and delivering a therapeutic agent to the adventitia of a vessel |
| 03/16/2006 | WO2005110442A3 Peritoneal dialysis solution |
| 03/16/2006 | WO2005110368A8 Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision |
| 03/16/2006 | WO2005109313A3 Enclosing drugs with synthetic oligonucleotides |
| 03/16/2006 | WO2005107711A3 Method and composition for treating rhinitis |
| 03/16/2006 | WO2005105070A3 Therapeutic antimicrobial compositions and methods |
| 03/16/2006 | WO2005092286A3 Metallic nano-particles and discrete polymer-coated nano-particles |
| 03/16/2006 | WO2005082942A3 Hydroxyethyl starch |
| 03/16/2006 | WO2005082781A3 Method for preparing adjustably bioresorbable sol-gel derived sio2 |
| 03/16/2006 | WO2005082330A3 Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same |
| 03/16/2006 | WO2005072679A3 Adjuvant formulation containing an oily emulsion with jojoba oil |
| 03/16/2006 | WO2005046561A3 Multilayer dosage form comprising a matrix that influences release of a modulatory substance |
| 03/16/2006 | WO2005044366A3 System and method for transdermal vaccine delivery |
| 03/16/2006 | WO2005037203A3 Methods and reagents for the treatment of immunoinflammatory disorders |
| 03/16/2006 | WO2005004917A3 Pharmaceutical composition for solubility enhancement of hydrophobic drugs |
| 03/16/2006 | WO2005004839A3 Stable pharmaceutical formulation |
| 03/16/2006 | US20060058736 Novel vaccine |
| 03/16/2006 | US20060058552 Solid preferably with an aspect ratio of 1 to 4 and a solubility in water at room temperature of at least 425 mg/ml. |
| 03/16/2006 | US20060058533 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 03/16/2006 | US20060058399 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 03/16/2006 | US20060058381 Pharmaceutical formulation comprising (r)-bicalitamide |
| 03/16/2006 | US20060058345 Use of papaverine-like vasodilator and pharmaceutical composition |
| 03/16/2006 | US20060058333 Analgesic compositions containing buprenorphine |
| 03/16/2006 | US20060058332 sublingual administration of N-cyclopropylmethyl-7 alpha -[1-(S)-hydroxy-1,2,2-trimethylpropyl]6,14-endoethano-6,7,8,14-tetrahydro-nororipavine, in combination with naloxone, naltrexone or nalmefene; synergistic mixtures for the treatment of pain in humans or animals |
| 03/16/2006 | US20060058300 Intermediates of bupropion metabolites synthesis |
| 03/16/2006 | US20060058279 Topical compositions comprising ascomycins |
| 03/16/2006 | US20060058277 Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| 03/16/2006 | US20060058273 A combination of a cephalosporin. prednisolone and a carrier to treat milk-producing animals having clinical mastis of the mammary gland; increased antiinflammatory efficiency without the immunosuppressive side effects; bovine mastitis; veterninary medicine |
| 03/16/2006 | US20060058251 Use of immunostimulatory nucleic acids containing unmethylated CpG dinucleotide sequences to treat viral infections; use with viral antigen in vaccine or without a viral antigen |
| 03/16/2006 | US20060058249 Efficient nucleic acid encapsulation into medium sized liposomes |
| 03/16/2006 | US20060057737 Multi-cap reservoir devices for controlled release or exposure of reservoir contents |
| 03/16/2006 | US20060057259 Production of capsules and particles for improvement of food products |
| 03/16/2006 | US20060057252 Composition containing calcium pantothenate and vitamin |
| 03/16/2006 | US20060057233 Coolant plant extract compositions containing monomenthyl succinate |
| 03/16/2006 | US20060057227 Throat spray |
| 03/16/2006 | US20060057225 Stable pharmaceutical composition useful for treating gastrointestinal disorders |
| 03/16/2006 | US20060057222 drug delivery device in the form of polymerized nanoparticles; combining water, NaCl, NaBr, ethylene oxide-propylene oxide triblock copolymers; one or more acrylic monomers, initiators such as azobisisobutyronitrile to produce a nonsolvent, mixing a solvent and a polymer with nonsolvent, phase separation |
| 03/16/2006 | US20060057221 Polymeric microparticulates for sustained release of drug and their preparation methods |
| 03/16/2006 | US20060057220 Fine spherical particles with satisfactory molecular orientation, spherical microcapsules comprising the same and processes for producing these |
| 03/16/2006 | US20060057219 Method for preparing a polymer micelle pharmaceutical preparation containing drug for injection |
| 03/16/2006 | US20060057218 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 03/16/2006 | US20060057217 Aqueous, non-alcoholic liquid powder formulations |
| 03/16/2006 | US20060057216 Low-obscuration image transmitting particulate ocular therapeutic formulations |
| 03/16/2006 | US20060057215 Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility |
| 03/16/2006 | US20060057214 Process for the produciton of cross-linked gelatin beadlets |
| 03/16/2006 | US20060057213 Drug delivery particles and methods of treating particles to improve their drug delivery capabilities |
| 03/16/2006 | US20060057212 Polyolefin additive composition comprising 3,4-dimethyl dibenzylidene sorbitol and p-methyl dibenzylidene sorbitol and method of using such composition in a polyolefin |
| 03/16/2006 | US20060057211 matrix-forming agent; a polyelectrolyte-amphiphilic agent adduct formed by an ionic association of a polyelectrolyte with a first amphiphilic agent and having a C4-C24 hydrocarbon chain, is in physical communication with the matrix-forming polymer, a coated magnetic field-responsive agent and biomaterial |
| 03/16/2006 | US20060057210 for oral administration, reducing the range in daily dosages required to control pain in human patients; specified mean maximum plasma concentration |
| 03/16/2006 | US20060057209 Methods, compositions and devices, including microfluidic devices, comprising coated hydrophobic surfaces |
| 03/16/2006 | US20060057208 Biocompatible drug delivery apparatus and methods |
| 03/16/2006 | US20060057207 Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
| 03/16/2006 | US20060057206 Controlled release nanoparticle active agent formulation dosage forms and methods |
| 03/16/2006 | US20060057205 Phenylepherine containing dosage form |
| 03/16/2006 | US20060057204 Pharmaceutical compositions containing venlafaxine |
| 03/16/2006 | US20060057203 Modified release formulations of oxcarbazepine and derivatives thereof |
| 03/16/2006 | US20060057202 Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
| 03/16/2006 | US20060057201 Multicomponent pharmaceutical dosage form |
| 03/16/2006 | US20060057200 Tablets with site- and time-controlled gastrointestinal release of active ingredient |
| 03/16/2006 | US20060057199 Orally disintegrating tablets of atomoxetine |
| 03/16/2006 | US20060057198 Drug delivery from embolic agents |
| 03/16/2006 | US20060057197 Pharmaceutical dosage forms having immediate release and/or controlled release properties |